By Associate Professor Yeh Chen Lee

Conference Abstracts

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z

Klingberg D; Bae S; Zhou D; Sim H-W; Cai R; Anazodo A; Grimison PS; Lewis CR; Lee YC, 2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570

Au-Yeung G; Bressel M; Prall O; Surace D; Andrews J; Mongta S; Lee YC; Gao B; Meniawy T; Baron-Hay SE; Black AJ; Kichenadasse G; Ananda S; Fox P; Bowtell D; Mileshkin LR, 2022, 'IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5515 - 5515, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5515

Mileshkin LR; Moore KN; Barnes EH; Lee YC; Gebski V; Narayan K; Bradshaw N; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Carlson M; Robison K; Rischin D; Stockler MR; Monk BJ, 2022, 'Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5531 - 5531, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5531

Smith D; Robledo K; Yip S; Cummins M; Kok P-S; Lee YC; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Lombard JM; Spurdle AB; Andrews J; Stockler MR; Mileshkin LR; Antill YC, 2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584

Scott C; Lee CK; Lee YC; Friedlander M; Hollis S; Diamante K; Davies C; Stockler M; Plebanski M, 2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page